Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

349.90DKK
24 May 2017
Change (% chg)

kr.-0.20 (-0.06%)
Prev Close
kr.350.10
Open
kr.348.70
Day's High
kr.353.80
Day's Low
kr.348.70
Volume
444,170
Avg. Vol
377,001
52-wk High
kr.363.40
52-wk Low
kr.212.70

Latest Key Developments (Source: Significant Developments)

Lundbeck Q1 EBIT at DKK 1.01 Billion, above expectations
Wednesday, 10 May 2017 01:43am EDT 

May 10 (Reuters) - H LUNDBECK A/S ::2017 GUIDANCE RAISED BASED ON STRONG REVENUE GROWTH AND IMPROVED PROFITABILITY .NOW EXPECTS REVENUE TO REACH DKK 16.5-17.3 BILLION AND PROFIT FROM OPERATIONS (EBIT) TO REACH DKK 3.6-4.0 BILLION FOR 2017.Q1 REVENUE DKK 4.21 BILLION (REUTERS POLL DKK 4.22 BILLION).Q1 EBIT DKK 1.01 BILLION (REUTERS POLL DKK 875 MILLION).  Full Article

Lundbeck enters a conditional agreement to sell part of its headquarters
Friday, 5 May 2017 05:28am EDT 

May 5 (Reuters) - LUNDBECK : :LUNDBECK ENTERS A CONDITIONAL AGREEMENT AND DIVESTS PART OF ITS HEADQUARTERS IN COPENHAGEN AND EXPECTS TO RAISE ITS FINANCIAL GUIDANCE BY DKK 200 MILLION.PROVIDED THAT PRE-SPECIFIED CONDITIONS ARE MET, LUNDBECK WILL RECEIVE A CASH PAYMENT OF DKK 378 MILLION IN DECEMBER 2017.TRANSACTION WILL HAVE A POSITIVE EFFECT ON P&L AND FINANCIAL GUIDANCE OF AROUND DKK 200 MILLION.  Full Article

Health Canada approves Otsuka and Lundbeck's REXULTI as a treatment for schizophrenia in adults
Friday, 17 Feb 2017 05:09pm EST 

H Lundbeck A/S : Health Canada approves Otsuka and Lundbeck's REXULTI(tm) (brexpiprazole) as a treatment for schizophrenia in adults .Lundbeck Canada - REXULTI will be co-marketed by two companies and is expected to become commercially available in Canada this spring.  Full Article

Lundbeck CEO says not concerned about Trump policies
Wednesday, 8 Feb 2017 05:06am EST 

Lundbeck CEO Kare Schultz says: Not concerned about the policies of U.S. President Donald Trump. . Doesn't think Trump policies can do anything of significance to affect Lundbeck. . No more layoffs planned as part of Lundbeck's cost cutting programme. . Certain to reach EBIT margin of 25 percent before 2020, says likely to reach the target in 2018. Further company coverage: [LUN.CO] (Reporting by Julie Astrid Thomsen, editing by Louise Heavens) ((julieastrid.thomsen@thomsonreuters.com;)).  Full Article

Lundbeck Q4 EBIT DKK 751 mln, above expectations
Wednesday, 8 Feb 2017 01:42am EST 

Lundbeck : Lundbeck continues to show solid revenue growth and strong improvement in profitability . Directors proposes to pay a dividend of 2.45 Danish crowns per share . For 2017, Lundbeck expects revenue of 16.3-17.1 billion crowns and EBIT of 3.4-3.8 billion crowns . Q4 revenue 4.17 billion crowns (Reuters poll 4.10 billion crowns) . Q4 EBIT 751 million crowns (Reuters poll 664 million crowns) .I am confident that we can deliver on our targets for coming years - Lundbeck’s President and CEO, Kare Schultz says in a statement.  Full Article

NNIT extends agreement with Lundbeck
Wednesday, 21 Dec 2016 04:18am EST 

Nnit A/S : Extends agreement with Lundbeck . Estimated total value of agreement consisting of three contracts will amount in high double-digit million Danish crown range .Agreement is effective as of January 1, 2017 and runs until end 2020, replacing existing agreement, which expires end 2017.  Full Article

H Lundbeck: FDA accepts sNDA for the expanded labeling of Abilify Maintena
Wednesday, 30 Nov 2016 09:02am EST 

H Lundbeck A/S : U.S. FDA accepts for review a supplemental new drug application to expand labeling of Abilify Maintena (Aripiprazole) for the treatment of Bipolar I disorder . If label expansion is approved, Abilify Maintena would offer prescribers a once-monthly long-acting injectable option in maintenance treatment of Bipolar I disorder in adults .Application seeks to expand Abilify Maintena label to include maintenance treatment for Bipolar I disorder.  Full Article

Lundbeck says alzheimer's drug late stage study fails
Thursday, 22 Sep 2016 12:01pm EDT 

H Lundbeck A/S : In first study, idalopirdine did not meet primary endpoint . Conclusions from first out of three phase 3 studies on idalopirdine in alzheimer's disease . Idalopirdine was safe and well tolerated .Two remaining studies, Starbeam and StarbrightII in phase 3 programme will continue as planned, data expected in first quarter of 2017.  Full Article

Lundbeck Q2 EBIT beats expectations; raises FY outlook
Wednesday, 24 Aug 2016 01:51am EDT 

H Lundbeck A/S : Q2 revenue 3.75 billion Danish crowns ($568.8 million) (Reuters poll 3.67 billion crowns) . Q2 EBIT 469 million crowns (Reuters poll 414 million crowns) . Now expects 2016 revenue of around 14.6 billion - 15.0 billion crowns compared to previously 14.2 billion - 14.6 billion crowns .2016 EBIT is expected to reach 1.5 billion - 1.7 billion crowns compared to 1.3 billion - 1.5 billion crowns.  Full Article

Lundbeck: Trintellix (vortioxetine) now available in US
Wednesday, 1 Jun 2016 10:29am EDT 

H Lundbeck A/S : Says Trintellix (vortioxetine) is now available in US . Says trade name for the vortioxetine product in US would be changed to Trintellix to avoid name confusion .Says formulation, indication and dosages of Trintellix remain the same as that of Brintellix.  Full Article

More From Around the Web

UPDATE 1-Lundbeck raises earnings guidance for the fourth time in 12 months

May 10 Danish drugmaker Lundbeck raised its financial guidance for the fourth time in 12 months as sales of its anti-epileptic drug Sabril was not dented by copycat competition, as Lundbeck had expected, its chief executive said on Wedneday.